Actinium Pharmaceuticals (ATNM) said Tuesday it is launching a clinical program consisting of trials studying Actimab-A in combination with either Merck's (MRK) Keytruda or Bristol Myers Squibb's (BMY) Opdivo for the treatment of multiple solid tumors.
Actimab-A is meant to improve the efficacy of the immunotherapies by targeting myeloid derived suppressor cells, the company said.
The Actimab-A trials will include several controlled, head-to-head studies that will evaluate the combination of Actimab-A with Keytruda and Opdivo in comparison with the two drugs alone.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。